Bruker Corporation (BRKR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $9.41B
Last updated: Nov 17, 2026 at 4:20 PM ET
Bruker Corporation (BRKR) Stock Chart
Bruker (BRKR) has a latest price of $61.36 on Nov 17, 2026, 11.0% below its 52-week high of $68.98. Its price rose 47.9% over the past 12 months. The month-end price rose 178.5% over the 10 years through Oct 2026, a compound annual rate of 10.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $93.94 in Mar 2024 and its lowest $20.49 in Oct 2016, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart BRKR with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for BRKR.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 4.7%, and over 6 months it rose 44.3%. The month-end price rose 0.1% over the 3 years through Oct 2026.
| Period | Change |
|---|---|
| 1 month | +10.8% |
| 3 months | +4.7% |
| 6 months | +44.3% |
| 12 months | +47.9% |
| 12 months, with dividends | +48.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +0.1% | 0.0% |
| 5 years | -28.9% | -6.6% |
| 10 years | +178.5% | +10.8% |
Price by Year
Its best calendar year was 2019, when the price rose 71.2%, and its weakest was 2024, when it fell 20.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $57.07 | +21.1% |
| 2025 | $47.11 | -19.6% |
| 2024 | $58.62 | -20.2% |
| 2023 | $73.48 | +7.5% |
| 2022 | $68.35 | -18.5% |
| 2021 | $83.91 | +55.0% |
| 2020 | $54.13 | +6.2% |
| 2019 | $50.97 | +71.2% |
| 2018 | $29.77 | -13.3% |
| 2017 | $34.32 | +62.0% |
Trading Range
The price is 3.0% above its 50-day average of $59.58 and 20.5% above its 200-day average of $50.94.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $61.36 | |
| 52-week high | $68.98 | -11.0% |
| 52-week low | $32.27 | +90.1% |
| 50-day average | $59.58 | +3.0% |
| 200-day average | $50.94 | +20.5% |
Price Risk
Over 3 years, its largest fall from a peak was 68.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.71 |
| Largest fall, 1 year | -39.8% |
| Largest fall, 3 years | -68.7% |
Valuation
Bruker traded at 25.7x earnings at the end of 2025, against a 5-year median of 27.3x and a 10-year median of 27.6x.
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About BRKR
What is BRKR's 1-year price change?
Bruker's price rose 47.9% over the past 12 months. With dividends included, the 12-month total return was 48.4%.
What is BRKR's 5-year price change?
Bruker's month-end price fell 28.9% over the 5 years through Oct 2026, a compound annual decline of 6.6%. These figures leave out dividends.
What is BRKR's 52-week high and low?
Bruker's 52-week high is $68.98 and its 52-week low is $32.27. Its latest price of $61.36 on Nov 17, 2026 is 11.0% below the high.
What is BRKR's beta?
Bruker's 1-year beta against the S&P 500 is 1.71, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 39.8%.
Is the BRKR chart free?
Yes. Advanced Charting for BRKR is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
BRKR pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts